MedTrace Logo

Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid

NCT06522984 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-07-26

No results posted yet for this study

Summary

Melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes.

Melasma is a name derived from the Greek word melas meaning black.It is characterized by the appearance of brownish or grayish symmetrical patches on sun-exposed skin, most commonly on the face. Compared to men, women are more likely to be affected.

Conditions

  • Refractory Melasma

Interventions

DRUG

Tranexamic acid injection

to evaluate and compare efficacy of: * Fractional Er: YAG laser combined with topical hydroquinone. * Intradermal injection of tranexamic acid combined with topical hydroquinone cream. * Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma.

Sponsors & Collaborators

  • Aswan University

    collaborator OTHER

  • Egymedicalpedia

    lead INDUSTRY

Principal Investigators

  • Moustafa Adam Ali El Taieb, Professor · Dermatology, Venereology and Andrology.Faculty of Medicine, Aswan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-06-01
Completion
2025-06-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06522984 on ClinicalTrials.gov